Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

CJC-1295 No DAC & Ipamorelin Mechanism: Research Application Comparison

Primary Mechanism GHRH receptor agonist. Extends pulse amplitude and duration by resisting DPP-4 degradation Ghrelin receptor (GHS-R1a) agonist. Triggers pulsatile GH secretion selectively Dual-pathway activation: GHRH primes secretory capacity while ghrelin r

This comparison does not assign a generated winner or score.

  • Primary Mechanism
  • GHRH receptor agonist. Extends pulse amplitude and duration by resisting DPP-4 degradation
  • Ghrelin receptor (GHS-R1a) agonist. Triggers pulsatile GH secretion selectively
  • Dual-pathway activation: GHRH primes secretory capacity while ghrelin receptor triggers release
  • Synergistic receptor-level interaction produces effects neither compound achieves alone
  • Plasma Half-Life
  • Approximately 30 minutes (vs 7 minutes for natural GHRH)
  • Approximately 2 hours with GH peak at 15–30 minutes
  • Overlapping pharmacokinetics during 90–120 minute pulse window
  • Half-life alignment ensures peak receptor occupancy coincides with natural pulsatile rhythm
  • IGF-1 Elevation
  • Moderate elevation sustained 4–6 hours post-dose (20–40% above baseline in rodent models)
  • Transient elevation 2–4 hours post-dose (15–30% above baseline)
  • 3–5× greater IGF-1 AUC than either compound alone (University of Virginia data)
  • Multiplicative effect indicates true synergy. Not just additive dosing
  • Secondary Hormones
  • Minimal ACTH/cortisol elevation (GHRH selectivity preserved)
  • No ACTH, cortisol, or prolactin elevation (ghrelin receptor selectivity confirmed)
  • Combined administration maintains selectivity. No cortisol spikes observed
  • Receptor selectivity preserved in combination. Critical for research protocols isolating GH effects
  • Receptor Downregulation Risk
  • Low. Short half-life preserves pulsatile pattern and prevents continuous receptor occupancy
  • Very low. Transient activation mimics endogenous ghrelin signaling
  • Minimal when dosed 1–2×/day aligned with natural pulses
  • Physiological pulsatility prevents negative feedback suppression that occurs with long-acting analogs
More references

Related material